BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.21 --0%
EPS Growth %: +25.0%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
DGICA, UXIN, TOWN, More
EPS Growth %: +25.0%
Financial Fact:
Interest and other income: 109K
Today's EPS Names:
DGICA, UXIN, TOWN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Grainger (GWW) Tops Q1 EPS by 2c, provides guidance
- Netlist (NLST) Misses Q1 EPS by 1c
- Hess Midstream Partners LP (HESM) Misses Q1 EPS by 5c, reaffirms guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
